ENDRA Life Sciences Inc. NDRA PHARMA
Company Overview
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.07.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +34.82% |
| 6 Months: | +72.66% |
| 3 Months: | +38.29% |
| 1 Month: | +28.37% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)60.66 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 27.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NDRA ENDRA Life Sciences Inc. PHARMA | 5.90 | -0.94 | $8.85M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 57.77K | 287.00K | 6.17K | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | 0 | 0 | 6.34K | 168.73K | 6.17K | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.47M | 1.30M | 1.37M | 1.62M | 2.17M |
| Operating Income | -373.46K | -494.31K | -605.11K | -360.70K | -1.06M | -910.93K | -2.84M | -1.82M | -2.36M | -2.75M | -2.33M | -2.64M | -3.10M | -2.89M | -3.26M | -2.58M | -3.20M | -2.65M | -2.86M | -3.57M | -3.42M | -2.94M | -2.99M | -3.13M | -2.78M | -2.23M | -1.51M | - | -1.47M | -1.30M | -1.37M | -1.62M | -2.17M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.42M | -1.27M | -1.33M | -1.58M | -2.13M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.04M | -1.23M | -1.60M | -3.17M | -1.31M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -379.48K | -729.11K | -977.90K | -741.62K | -1.43M | -908.91K | -2.83M | -1.85M | -2.76M | -2.75M | -2.33M | -3.41M | -3.32M | -2.89M | -3.26M | -2.27M | -3.20M | -2.66M | -2.86M | -3.59M | -3.44M | -2.94M | -2.56M | -3.10M | -2.78M | -2.23M | -2.35M | - | -1.04M | -1.23M | -1.60M | -3.17M | -1.31M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.54 | - | -1.86 | -1.71 | -2.10 | - | -1.09 |
| R&D Expense | 198.88K | 103.64K | 137.54K | 95.81K | 174.72K | 300.53K | 1.67M | 839.76K | 1.16M | 1.77M | 1.30M | 1.47M | 1.52M | 1.49M | 1.77M | 1.14M | 1.74M | 1.17M | 1.21M | 1.85M | 1.83M | 1.39M | 1.40M | 1.63M | 1.04M | 716.37K | 794.44K | - | 528.68K | 381.06K | 432.11K | - | 776.41K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 515.58K | 351.62K | 6.17K | 0 | 0 | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 279.70K | 178.84K | 6.17K | 0 | 0 | 0 | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | 13.16M | 10.52M | 10.82M | 5.76M |
| Operating Income | -1.79M | -4.63M | -9.02M | -10.84M | -11.50M | - | -13.16M | -10.52M | -10.82M | -5.76M |
| EBITDA | - | - | - | - | - | - | -12.92M | -10.25M | -10.61M | -5.61M |
| Interest Expense | - | - | - | - | - | 0 | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | -13.18M | -10.06M | -11.51M | -7.03M |
| Tax Provision | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Net Income | -2.78M | -5.38M | -9.80M | -13.31M | -11.73M | - | -13.18M | -10.06M | -11.51M | -7.03M |
| Diluted EPS | - | - | - | - | - | - | -7,980.00 | -2,766.85 | -56.94 | -8.93 |
| R&D Expense | 495.38K | 1.93M | 4.72M | 6.57M | 5.92M | 5.48M | 6.55M | 5.00M | 3.19M | 1.85M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 490.76K | 6.12M | 7.22M | 7.18M | 8.76M | - | 9.27M | 6.75M | 4.45M | 3.85M |
| Current Assets | - | - | - | - | - | - | 5.38M | 3.03M | 3.43M | 967.97K |
| Cash & Equivalents | - | - | - | - | - | - | 4.89M | 2.83M | 3.23M | 762.37K |
| Inventory | - | - | - | - | - | 1.28M | 2.64M | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | 1.38M | 848.21K | 974.58K | 2.42M | 1.60M | - | 2.07M | 1.10M | 1.89M | 1.59M |
| Current Liabilities | 1.38M | 848.21K | 974.58K | 2.07M | 986.66K | - | 1.70M | 903.10K | 605.23K | 750.96K |
| Long Term Debt | - | - | - | - | - | 28.48K | - | - | - | - |
| Total Debt | - | - | - | - | - | - | 546.63K | 394.40K | 584.42K | 492.35K |
| Total Equity | -893.77K | 5.28M | 6.25M | 4.76M | 7.17M | - | 7.20M | 5.66M | 2.56M | 2.26M |
| Shares Outstanding | - | - | - | - | - | - | 1.81K | 5.94K | 536.91K | 1.18M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.32M | -3.30M | -7.70M | -8.59M | -10.75M | - | -12.77M | -9.55M | -7.40M | -5.18M |
| Investing Cash Flow | 0 | -7.86K | -100.00K | -43.59K | -75.33K | - | -202.58K | -24.72K | -12.80K | -3.02M |
| Financing Cash Flow | 1.44M | 8.77M | 8.67M | 8.34M | 11.88M | - | 8.40M | 7.52M | 7.81M | 5.73M |
| Capital Expenditure | - | -7.86K | -100.00K | -43.59K | -75.33K | - | -202.58K | -33.88K | -16.00K | -3.02M |
| Free Cash Flow | - | -3.31M | -7.80M | -8.63M | -10.82M | - | -12.97M | -9.58M | -7.42M | -8.20M |
| Net Change in Cash | - | - | - | - | - | - | -4.57M | -2.06M | 395.57K | -2.47M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 54.3% | 50.9% | 100.0% | - | - | - | - | - | - | - |
| Operating Margin % | -347.5% | -1,315.6% | -146,080.5% | - | - | - | - | - | - | - |
| Net Margin % | -538.3% | -1,529.2% | -158,669.6% | - | - | - | - | - | - | - |
| ROE % | 310.5% | -101.9% | -156.8% | -279.5% | -163.6% | - | -182.9% | -177.8% | -449.5% | -310.9% |
| ROCE % | 200.5% | -87.7% | -144.3% | -212.5% | -147.9% | - | -173.8% | -179.8% | -281.2% | -185.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Altium Capital Management, LLC | 3.95% | 59.27K | $326.00K |
| 2 | Citadel Advisors Llc | 2.00% | 29.92K | $164.58K |
| 3 | Citizens Financial Group Inc/RI | 1.89% | 28.40K | $156.20K |
| 4 | Geode Capital Management, LLC | 0.99% | 14.91K | $82.00K |
| 5 | Vanguard Fiduciary Trust Co | 0.67% | 10.12K | $55.66K |
| 6 | Vanguard Capital Management LLC | 0.49% | 7.34K | $40.36K |
| 7 | Morgan Stanley | 0.24% | 3.55K | $19.50K |
| 8 | Tower Research Capital LLC (TRC) | - | 58 | $319 |
| 9 | Northwestern Mutual Wealth Management Company | - | 19 | $104 |
| 10 | UBS Group AG | - | 68 | $374 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NDRA
Endra Life Sciences Stock Price Forecast. Should You Buy NDRA? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTFBrblBzclIwMDhldGhwVTZnQWdXN1NNQm9pUnpNX2hWU3NWSFF4MUYzLUVOMTkyTE40NkFZd3R1ZGY2cHh5SndmNA?oc=5" target="_blank">Endra Life Sciences Stock Price Forecast. Should You Buy NDRA?</a>&nb…
(NDRA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNREJHVjk4bE9NSEwtS3ZZMlc5XzllV1Y2QVZFWGR5RjFiaWU1clZ2XzFqNzcteXVvNC1YLVhhdDAxRnhMWHk4UXFxamJZSFhQdHlnSC1sY2NHN0Y5ODE2QlhncVpjcXU5dVhnTlZPekppZnZZSFg3N2QxS2dHcFFpdnRWOVloR3NmSzdabi…
NDRA Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9wQWQtVnJkbVREbmNTYV90WkhHdXhFZi1HekNEQms2S2VBaDdTMGwxS3djV1B3YTB2XzlOWU0wWU5BZlNKallqRzBQeUM5M2ExekQzNUZHbnZpbW9FQXRlZDd4UWhjWmVHa3FkdzBpMFV0YTdoQ2RyMDB3?oc=5" target="_blank">NDR…
ENDRA Life Sciences (NASDAQ: NDRA) shares ASP Isotopes helium plant update - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNQmxzSk9iZjdYVXlXMFF1Yk5xdHBrbDNzZV9nUncyUHY5cEFFdjhZSGt1a2t6dk9GMEMxSGs1T0xtUzkyYVRPQl9MMGxPZXIzeFhhc2JZMVV3b1E2UUVJX0dCZms4TmVuYlRzYXB5SmhEYzE4VTdjSWw0OFJQSENES3FrRll0QnIzbGNzbH…
NDRA - ENDRA Life Sciences Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBpYkZQQzZGUjhoRHhIbW41VlpxZmdXVzhMcE16Y25JSmk5T2RlMXl6blpJVl8waVNGYW5qUy1ULTV2MW9Gc1E?oc=5" target="_blank">NDRA - ENDRA Life Sciences Inc Stock Price and Quote</a> <fon…
ENDRA Life Sciences Reports $159,944 Second-Quarter 2026 Net Income - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPMURRQjZWZFJ6blpfNzM5TE9WbEZ0WnIyUXBoeVI2WXJITGZSOUttelNBVUd3c2ZxSm4tSXVESjhaWXI4NHZfNkNJVkRNc2ZhZXN3NzFDX3VSWHh0cHIteWJXbHIxQzZubjc3RzZwd1N6emJWUl9tWXZZNHRYNEYyMFJaeUVIMkRMU0phRE…
NDRA — Frequently Asked Questions
What is the current share price of ENDRA Life Sciences Inc. (NDRA)?
As of 2026-09-19 21:16 PDT, ENDRA Life Sciences Inc. (NDRA) trades at $5.90 on NasdaqCM. Its 52-week range is $3.26 to $8.12.
What is the market capitalisation of NDRA?
ENDRA Life Sciences Inc. (NDRA) has a market capitalisation of $8.85M on NasdaqCM.
What is the P/E ratio of NDRA?
NDRA trades at a trailing price-to-earnings (P/E) ratio of -0.94. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.31.
Is NDRA a good stock to buy?
This page provides a data-driven analysis of ENDRA Life Sciences Inc. (NDRA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.